A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults

Trial Profile

A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs NanoFlu vaccine-Novavax (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Novavax
  • Most Recent Events

    • 13 Jun 2018 According to Novavax media release, data from this trial was published in the New England Journal of Medicine (NEJM).
    • 13 Jun 2018 Results presented in the Novavax media release.
    • 09 May 2018 According to Novavax media release, data from this trial were presented at the World Vaccine Congress meeting in April 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top